An investigation into the potential of SarAr for Use in 64Cu radioimmunotherapy

Nadine Di Bartolo, Suzanne V. Smith, Eric Hetherington, Alan Sargeson

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu.

Original languageEnglish
Pages (from-to)1261-1270
Number of pages10
JournalAustralian Journal of Chemistry
Issue number10
Publication statusPublished or Issued - 2009
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)

Cite this